UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 360

Sortiert nach

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6

British journal of cancer, 2011-06, Vol.105 (1), p.139-145

2011

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic drugs in ovarian cancer

British journal of cancer, 2009-01, Vol.100 (1), p.1-7

2009

Link zum Volltext

Verfügbarkeit prüfen

Thrombosis in ovarian cancer: a case control study

British journal of cancer, 2014-03, Vol.110 (5), p.1118-1124

2014

Link zum Volltext

Verfügbarkeit prüfen

The clinical potential of antiangiogenic fragments of extracellular matrix proteins

British journal of cancer, 2005-10, Vol.93 (9), p.967-972

2005

Link zum Volltext

Verfügbarkeit prüfen

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy

Annals of oncology, 2010-10, Vol.21 (10), p.1982-1989

2010

Link zum Volltext

Verfügbarkeit prüfen

Heparan sulphate synthetic and editing enzymes in ovarian cancer

British journal of cancer, 2007-05, Vol.96 (10), p.1544-1548

2007

Link zum Volltext

Verfügbarkeit prüfen

Accessing cancer services in North West England: the Chinese population

European journal of cancer care, 2014-07, Vol.23 (4), p.570-581

2014

Link zum Volltext

Verfügbarkeit prüfen

Does clinical trial participation improve outcomes in patients with ovarian cancer?

ESMO open, 2016, Vol.1 (4), p.e000057-e000057, Article e000057

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib and randomised phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer

Annals of oncology, 2018-10, Vol.29, p.viii342-viii342

2018

Link zum Volltext

Verfügbarkeit prüfen

Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma

British journal of cancer, 2008-07, Vol.99 (2), p.253-258

2008

Link zum Volltext

Verfügbarkeit prüfen

Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition

Journal of human nutrition and dietetics, 2020-08, Vol.33 (4), p.550-556

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

Cancer chemotherapy and pharmacology, 2008-04, Vol.61 (4), p.579-585

2008

Link zum Volltext

Verfügbarkeit prüfen

Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3

Annals of oncology, 2018-10, Vol.29, p.viii338-viii339

2018

Link zum Volltext

Verfügbarkeit prüfen

Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment

Annals of oncology, 2018-10, Vol.29, p.viii336-viii336

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

British journal of cancer, 2003-10, Vol.89 (7), p.1152-1154

2003

Link zum Volltext

Verfügbarkeit prüfen

A novel discharge pathway for patients with advanced cancer requiring home parenteral nutrition

Journal of human nutrition and dietetics, 2019-08, Vol.32 (4), p.492-500

2019

Link zum Volltext

Verfügbarkeit prüfen

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer

British journal of cancer, 2006-01, Vol.94 (1), p.55-61

2006

Link zum Volltext

Verfügbarkeit prüfen

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK

Clinical oncology (Royal College of Radiologists (Great Britain)), 2016-12, Vol.28 (12), p.760-765

2016

Link zum Volltext

Verfügbarkeit prüfen

2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma

International journal of gynecological cancer, 2019-09, Vol.29 (Suppl 3), p.A1-A2

2019

Link zum Volltext

Verfügbarkeit prüfen

Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A28-A29

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A27-A28

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

British journal of cancer, 2003-10, Vol.89 (7), p.1152-1154

2003

Link zum Volltext

Verfügbarkeit prüfen

3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

International journal of gynecological cancer, 2020, Vol.30 (Suppl 3), p.A2-A3

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5009-5009

2011

Link zum Volltext

Verfügbarkeit prüfen

Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13580-e13580

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 360

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(340)
Mit Volltextzugriff
(283)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(202)
Life Sciences & Biomedicine
(185)
Humans
(162)
Female
(88)
Oncology
(62)
Biological And Medical Sciences
(57)
Ovarian Cancer
(52)
Middle Aged
(50)
Animals
(49)
Biochemistry & Molecular Biology
(48)
Aged
(47)
Male
(43)
Adult
(36)
Medical Sciences
(35)
Chemotherapy
(28)
Ovarian Neoplasms - Drug Therapy
(28)
Tumors
(28)
Fundamental And Applied Biological Sciences. Psychology
(23)
Ovarian Neoplasms - Pathology
(23)
Patients
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6

Antiangiogenic drugs in ovarian cancer

Thrombosis in ovarian cancer: a case control study

The clinical potential of antiangiogenic fragments of extracellular matrix proteins

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy

Heparan sulphate synthetic and editing enzymes in ovarian cancer

Accessing cancer services in North West England: the Chinese population

Does clinical trial participation improve outcomes in patients with ovarian cancer?

A phase Ib and randomised phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer

Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma

Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3

Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

A novel discharge pathway for patients with advanced cancer requiring home parenteral nutrition

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK

2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma

Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age

Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3

A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma

Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC)

Suchergebnisse filtern